Establishment and validation of a UPLC-MS/MS bioassay for the quantification of infigratinib in rat plasma

Infigratinib (INF) is a fibroblast growth factor receptor (FGFR)-specific tyrosine kinase inhibitor for the therapy of advanced cholangiocarcinoma. However, CYP3A4 polymorphisms and CYP3A4 inducers or inhibitors might affect the pharmacokinetics of INF. Clinical evaluation of drug-drug interactions...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Xuegu Xu, Chaojie Chen, Ya-nan Liu, Xiaolei Meng, Jian-ping Cai, Ren-ai Xu
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2022-07-01
Colecção:Arabian Journal of Chemistry
Assuntos:
Infigratinib
SD rat
UPLC-MS/MS
Pharmacokinetics
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S187853522200209X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados